Our Approach
George Medicines is not a traditional drug development company. We take existing, best-in-class treatments and formulate them into single pill combinations. These are intended to provide the optimal balance of high efficacy and improved safety, with potential for significant improvements in clinical outcomes and long-term adherence to treatment.
No.2 Fact
According to the W.H.O., only 50% of patients in developed countries who suffer from chronic diseases adhere to treatment recommendations. In developing countries, when taken together with poor access to health care, lack of appropriate diagnosis and limited access to medicines, poor adherence is threatening any effort to tackle chronic conditions such as hypertension. Using a low dose can often achieve much of the benefits, while avoiding many of the side effects, from a particular medicine. Combining multiple medicines can ensure a high efficacy overall. Reference
Fixed-dose combinations for non-communicable diseases
George Medicines’ drug development programs target non-communicable diseases (NCDs), the world’s leading causes of death and disability. Our innovative, single-pill combinations, in novel and unique dosage strengths, would reduce the need for patients to take multiple sets of pills daily and offer the potential for improvements in medication adherence.
No.3 Fact
NCDs are responsible for 71 per cent of global deaths annually. According to Access Accelerated 15 million people who die from NCDs are between 30 and 69 years old. Most of these are in low- and middle-income countries. The premature deaths of these individuals, during their most economically productive years, have a significant economic impact on these countries. Reference
Affordability & Accessibility
By designing treatment combinations in a single pill, George Medicines is looking to make a socio-economic impact on patients’ lives as well as helping them to live better and longer. We strive to make better treatments for all.
Our partners know the local markets and populations well, enabling our medicines to reach the patients who need them in the most affordable way.